Adjuvant Therapy of Nivolumab Combined With Ipilimumab Versus Nivolumab Alone in Patients With Resected Stage IIIB-D or Stage IV Melanoma (CheckMate 915)

Ipilimumab and nivolumab have each shown treatment benefit for high-risk resected melanoma. The phase III CheckMate 915 trial evaluated adjuvant nivolumab plus ipilimumab versus nivolumab alone in patients with resected stage IIIB-D or IV melanoma. PATIENTS AND METHODS: In this randomized, double-bl...

Descripción completa

Detalles Bibliográficos
Autores principales: Weber, Jeffrey S., Schadendorf, Dirk, Del Vecchio, Michele, Larkin, James, Atkinson, Victoria, Schenker, Michael, Pigozzo, Jacopo, Gogas, Helen, Dalle, Stéphane, Meyer, Nicolas, Ascierto, Paolo A., Sandhu, Shahneen, Eigentler, Thomas, Gutzmer, Ralf, Hassel, Jessica C., Robert, Caroline, Carlino, Matteo S., Di Giacomo, Anna Maria, Butler, Marcus O., Muñoz-Couselo, Eva, Brown, Michael P., Rutkowski, Piotr, Haydon, Andrew, Grob, Jean-Jacques, Schachter, Jacob, Queirolo, Paola, de la Cruz-Merino, Luis, van der Westhuizen, Andre, Menzies, Alexander M., Re, Sandra, Bas, Tuba, de Pril, Veerle, Braverman, Julia, Tenney, Daniel J., Tang, Hao, Long, Georgina V.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2023
Materias:
ORIGINAL REPORTS
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9870220/
https://www.ncbi.nlm.nih.gov/pubmed/36162037
http://dx.doi.org/10.1200/JCO.22.00533

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9870220/
https://www.ncbi.nlm.nih.gov/pubmed/36162037
http://dx.doi.org/10.1200/JCO.22.00533

Ejemplares similares